Skip to main content
. 2013 May 16;33(6):441–449. doi: 10.1007/s40261-013-0085-x

Fig. 2.

Fig. 2

Mean plasma oxycodone concentrations following intranasal dosing over time in the full analysis set. OC-F finely crushed original formulation of oxycodone-HCl controlled release, ORF-C coarsely crushed reformulated oxycodone-HCl controlled release, ORF-F finely crushed reformulated oxycodone-HCl controlled release